Enanta Pharmaceuticals Inc (ENTA)

[alertmeipp]

dewophile and DewDiligence - to a layman like me, ENTAs RSV program seems to be more advanced and promising than others, so any particular reasons they haven’t been able to secure a nice partnership or buyout for RSV?

PFEs spent 500mm for an inferior (now bursted) program, ENTAs program should worth at least that?

Actually, same thing for 235, COVID isn’t dead, just not in news daily anymore. COVID drug still take in billions of sales, why can’t ENTA get a partnership for it?

Is there some weakness in their deal making strategy?

The insider owns significant shares, do they get too greedy because of that?